Wed, Mar 6th 2024
Alcon aims for growth with a $12 billion revenue target by 2027, post-Novartis spin-off. CEO David Endicott remains optimistic despite market challenges.
Following its spin-off from Novartis, the ophthalmology leader Alcon is on a mission for growth. Under CEO David Endicott, Alcon sees it’s self reaching a $12 billion sales milestone by 2027.
Despite facing headwinds such as a strong US dollar and inflationary pressures, Endicott’s outlook for 2024 remains bullish.
Sustaining our current mid-single-digit growth rate should steer us to the $12 billion target.
CEO David Endicott
Post the Novartis spin-off, Alcon has achieved its transformation objectives and is now progressing steadily.
Endicott also shed light on the forthcoming AR-15512 dry eye treatment’s market debut, anticipating FDA submission by mid-2024 and a hopeful launch in summer 2025.
On the acquisition front, Alcon’s strategy remains unchanged. Endicott explained, “We often invest in unique, smaller patented ideas that augment our R&D. A billion-dollar acquisition isn’t appealing currently.”
©Keystone/SDA
English 
German 
French 
Spanish 
Arabic